Chongkundang Launches R&D Specialist Subsidiary "Newrateon" and Appoints Donghan Won as CEO
Providing Comprehensive Professional Services Across All Stages of Research and Development
Chongkundang announced on the 9th that it had established a new research and development specialized subsidiary called Newrateon (NURATEON) and held its inauguration ceremony on the 8th at the Hyosong Research Institute in Dongbaek District, Yongin City, Gyeonggi Province. The inauguration ceremony was attended by over 100 executives and employees, including Heenam Choi, CEO of Chongkundang Holdings, and Donghan Won, CEO of Newrateon.
On the 8th, Won Dong-han, CEO of Neurateon, a research and development specialized company, gave a greeting at the inauguration ceremony held at Hyojong Research Institute in Dongbaek District, Yongin City. Chongkundang
View original imageNewrateon provides comprehensive research and development services, including new drug formulations, improved drugs, generics, OTC development, analytical research, formulation research, and DDS (Drug Delivery System) research, based on the R&D capabilities accumulated by Chongkundang’s Hyosong Research Institute. The company aims to expand its customer base to domestic and international pharmaceutical and biotechnology companies by developing proprietary new products, technology transfer, and customized research and development services, striving to grow as a technology-driven R&D platform company.
The company name, Newrateon, combines “New Era,” signifying a new age, and “Teon,” derived from “Technology Innovation.”
On this day, Newrateon presented its vision as “a research and development platform company opening a new era through technological innovation,” and its mission as “contributing to human health through differentiated technology and innovative new products.” Its core values are Technology, Collaboration, and Innovation.
Donghan Won, a former executive director at Chongkundang Research Institute, has been appointed as CEO of Newrateon. CEO Won holds a Ph.D. in Pharmacy from Pusan National University and is an expert in the pharmaceutical and biotechnology industry, having conducted technical research for 23 years.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In his inauguration speech, Donghan Won, CEO of Newrateon, stated, “Newrateon is a technology-based R&D platform company that provides the best services to customers and partners, backed by outstanding research personnel and expertise. We will differentiate ourselves through technology and expand through collaboration, ushering in a new era for the future pharmaceutical industry.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.